Market Updates

Enzymotec, Nics Sign Agreement

Enzymotec, Migdal HaEmeq, Israel, has signed an exclusive agreement with Korea-based Nics Corporation Ltd. According to the agreement, Nics will exclusively market Enzymotec’s InFat product to the dairy and infant formula markets in Korea. InFat is designed to imitate mother’s milk in infant formulas.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters